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Abstract
Introduction The innate immune system orchestrates in-
flammatory responses to microorganisms or danger-associ-
ated molecular patterns generated, for example, by the
deposition of uric acid in the joints of gout patients. The
innate immune system comprises multiple germ-line
encoded receptors, of which the nucleotide-binding domain
and leucine-rich repeat containing receptors (NLRs) are
crucial for the maturation of pro-inflammatory cytokines.
NLRs oligomerize to form large multi-protein complexes
termed inflammasomes that generate active caspase-1 frag-
ments leading to the cleavage and secretion of mature
cytokines such as IL-1β and IL-18.
The regulation of multiple inflammasomes At least four
independent inflammasomes have been identified, NLRP1,
NLRP3, IPAF, and AIM2. These inflammasomes assemble
in response to different stimuli to confer specificity and are
also subject to negative regulatory mechanisms to ensure
that once a productive inflammatory response has been
mounted, inflammatory cytokine production is restrained.
Treatment of auto-inflammatory disorders A number of
human conditions are characterized by unrestrained inflam-
masome activation. As much is now known about how
inflammasomes are regulated, it is hoped that this can be
channeled into the development of novel therapeutics, for
example, those that may block the upstream activation and
assembly of inflammasomes.
Keywords Inflammasome.NLR proteins.auto-
inflammatory disorder.caspases.DAMP.PAMP.IL-1β
Components of the Innate Immune System Coordinate
Inflammatory Responses
An inflammatory response consists of a multifactorial network
of intracellular and chemical signals that initiate and maintain a
host response designed to eliminate pathogens and heal the
damagedtissue.Thisresponseisinitiatedbytheinnateimmune
system, which, unlike the adaptive system, does not depend on
somatic recombination to generate a highly specific repertoire
of receptors for pathogen recognition. Key sensors of these
“danger” signals expressed on cells of the innate immune
system such as macrophages and dendritic cells include
germline-encoded receptors that are classified according to
thepresenceofvariablenumbersandtypesofbindingdomains,
cellular localization, and substrate specificity (Fig. 1). These
include transmembrane Toll-like receptors (TLRs), RIG-1-like
helicases (RLRs), and the nucleotide-binding domain and
leucine-rich repeat-containing receptors (NLRs).
These receptor complexes detect pathogen-associated
molecular patterns (PAMPs) that represent largely invariant
microbial components, thus enabling a more rapid response
to a broader range of stimuli. For example, mammalian
cells detect unique nucleic acid structures or the presence of
cell wall components that specify the “otherness” of the
invading microorganism. In contrast, damage (self)-associ-
ated molecular patterns (DAMPs) perpetuate immune
responses in a non-infectious manner to clear agents that
have normal physiological roles but, as a consequence of a
disease state, have become mislocalized or even released
from the cell. Signaling downstream of these receptors
engages common effector machinery, including NFκB/AP-
1-dependent transcription of pro-inflammatory cytokines and
chemokines, interferon regulatory factor (IRF)-dependent
induction of type I interferon-mediated antiviral response
and assembly of a large multiprotein scaffold termed the
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DOI 10.1007/s10875-010-9383-8“inflammasome” (Fig. 1). This review will focus on the
inflammasome as an effector of pro-inflammatory cytokine
production and how knowledge of the regulation of this
signaling cascade can be exploited for therapeutic benefit.
Following an inflammatory stimulus, oligomerization of
NLR components catalyzes the recruitment of inactive pro-
caspase-1 either by direct, homotypic caspase activation
and recruitment domain (CARD) interaction in the case of
NLRP1 and IPAF1 or via binding to the adaptor protein
ASC in the cases of NLRP3 and absent in melanoma 2
(AIM2) (Fig. 1). ASC is a central player in the formation of
multiple inflammasome complexes and when abolished
leads to a specific reduction in IL-1β and IL-18 secretion
without concomitant attenuation in the production of TNF-
α and IL-6 following stimulation [1]. Caspases have long
been established as executioners of the apoptotic response
but a subclass of these cysteine proteases (mouse caspase-1,
-11, and -12 and human caspase-1, -4, and -5) are now
known to contribute to inflammation, as their main
substrates are the pro-inflammatory cytokines proIL-1β
and proIL-18. Caspase-1 is synthesized as an inactive
zymogen, and the induced proximity of multiple caspase-1
zymogens within the inflammasome complex leads to
autocatalytic activation and production of potent p10 and
p20 caspase-1 fragments. As caspase-1
−/− animals are
highly resistant to endotoxic shock due to defective
maturation of these cytokines [2, 3], it is clear that this
caspase is responsible for the maturation of IL-1β and IL-
18 by cleavage of their precursor forms. The pleiotropic
activity of mature IL-1β is responsible for increased
infiltration of leukocytes into the site of injury to neutralize
and phagocytose pathogens, induction of fever, and
regulation of hematopoiesis. Due to the potentially delete-
rious effect of unrestrained IL-1β secretion, IL-1β is
subjected to two levels of regulation: firstly, increased
NFκB-dependent transcription of the pro-form and second-
ly, proteolytic maturation via cleavage by caspase-1. In
contrast, the inactive form of IL-18 is constitutively
expressed and, therefore, only requires cleavage by
caspase-1 to become active.
Conferring Specificity upon an Inflammatory Response
Genetic studies in mice have identified at least three
independent inflammasomes that assemble in response to
Fig. 1 The complexity of innate immune receptor surveillance and
inflammasome activation. Detection of pathogens by the innate
immune system is dependent on the function of multiple receptor
classes that differ in localization, stimulus specificity, regulation, and
function. TLRs are found on the cell surface and within endosomes,
whereas the RLR and NLR receptors function within the cytosol. The
production of mature IL-1β requires NFκB-dependent transcriptional
upregulation followed by proteolytic maturation mediated by the p10
and p20 fragments of caspase-1. LT lethal toxin, MDP muramyl
dipeptide, CARD caspase activation and recruitment domain, PYD
pyrin, NAD NACHT-associated domain, NLR Nod-like receptor, AIM2
absent in melanoma, PAMPs pathogen-associated molecular pattern,
RIG-1 retinoid acid-inducible gene-1, RLR RIG-1-like receptor, TLR
Toll-like receptor, IL-1 interleukin-1, AP-1 activator protein-1, DAMP
danger-associated molecular pattern, MDA5 melanoma differentiation-
associated gene-5, NFκB nuclear factor κB, NOD nucleotide-binding
and oligomerization domain, LRR leucine repeat region, IRF interferon
regulatory factor
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NLR protein. These are the NLRP3, NLRP1, and IPAF
inflammasomes. Although numerous other NLR proteins
havebeenidentified,thesearetheonlyonesfirmlyestablished
bygeneticandbiochemicalexperimentstohavephysiological
roles. The two distinguishing features of these intracellular
immune receptors are a NACHT nucleotide-binding domain
andaC-terminalleucine-richrepeatregion(LRR;Fig.1). The
NACHT domain belongs to a large superfamily of NTPase
domains and is proposed to mediate ATP-dependent oligo-
merization of multiple NLR proteins. LRR regions form
protein–protein interaction motifs found in a variety of
proteins with diverse functions and consequently confer the
sensor activity of the NLR protein. In addition to these NLR-
dependent inflammasomes, double-stranded DNA was
shown to trigger caspase-1 activation mediated by the HIN-
200 protein AIM2.
The NLRP3/Cryopyrin Inflammasome
Of the three NLRP inflammasomes identified to date,
NLRP3 remains the most extensively characterized owing
to the diversity of its activating stimuli (Table 1). These
include bacterial RNA, ATP, a range of PAMPs, pore-
forming toxins, and structural aggregates such as mono-
sodium urate and calcium pyrophosphate that are produced
as by-products of a disease state such as gout. In addition,
environmental exposure to crystalline agents such as
asbestos and silica induce NLRP3-dependent inflamma-
some activation and consequently has been implicated in
the etiology of asbestosis and silicosis. This observation has
catalyzed much interest in the identification of how such
structurally diverse ligands can activate a common inflam-
masome pathway. Three proposed models predominate:
translocation of extracellular NLRP3 agonists into the
cytosol to facilitate direct ligand–receptor interaction,
lysosomal destabilization, and the existence of a common
secondary messenger.
The efflux of potassium from the cell underpins the
activity of the majority of NLRP3 agonists and represents a
more general detection of perturbed cellular homeostasis.
For example, ATP is a DAMP that triggers a sequence of
events culminating in the opening of the hemichannel
pannexin-1, which is recruited upon activation of the
purinergic P2X7 receptor. Knockdown and pharmacologi-
cal inhibition of pannexin-1 confirmed that this process is
absolutely required for K
+ efflux, efficient NLRP3-
dependent caspase-1 activation, and IL-1β secretion in
response to LPS plus ATP. The formation of this pore also
presumably enables the translocation of pathogens into the
cytosol to activate the NLRP3 inflammasome by direct
ligand–receptor interaction, although to date, no such
interactions have been demonstrated. The lysosomal desta-
bilization model posits that internalization of particulate
matter by phagocytes causes rupture and cytosolic release
of these agents, which are subsequently detected by the
NLRP3 inflammasome [4].
However, in terms of accounting for the diversity of
NLRP3 activators, the most attractive model is the
existence of a common secondary messenger. It can be
envisaged that this messenger would have similar properties
to classical messengers such as cAMP, including rapid
spatial and temporal regulation, diffusibility, and sensitivity
to negative feedback. This may provide clues to aid in the
identification of this messenger, which to date remains
elusive. It is certainly intriguing that reactive oxygen
species (ROS) scavengers were sufficient to block inflam-
masome activation by a range of NLRP3 agonists [5], but
Table 1 Inflammasome Activators
Inflammasome Activators Class
NLRP1 Anthrax lethal toxin PAMP
MDP PAMP
NLRP3 Sendai Virus
Influenza A Virus
Adenovirus Virus
Staphylococcus aureus Bacteria
Listeria monocytogenes Bacteria
Escherichia coli Bacteria
Mycobacterium marinum Bacteria
Neisseria gonorrhoeae Bacteria
Candida albicans Fungus
MDP PAMP
Bacterial RNA PAMP
Lipopolysaccharide PAMP
poly(I:C) PAMP
Nigericin PAMP
Listeriolysin O PAMP
Aerolysin PAMP
Maitotoxin PAMP
α-Toxin PAMP
ATP DAMP
Hyaluronan DAMP
Uric acid DAMP
Asbestos DAMP
Silica DAMP
β-Amyloid DAMP
Ipaf Flagellin PAMP
Salmonella typhimurium Bacteria
Legionella pneumophila Bacteria
Shigella flexneri Bacteria
Pseudomonas aeruginosa Bacteria
AIM2 Double-stranded DNA PAMP
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lacking functional phagosomal NADPH oxidase did not
exhibit augmented NLRP3 activation [4] and ROS has also
been shown to inhibit caspase-1 activity [6]. Certainly these
pathways to NLRP3 inflammasome activation need not be
mutually exclusive, and further work is required to
delineate the relative contribution of each to antimicrobial
defense.
The IPAF Inflammasome
The absence of IPAF in macrophages results in profound
resistance to inflammasome activation catalyzed by infec-
tion with Gram-negative bacteria such as Salmonella
typhimurium, Legionella pneumophila, Pseudomonas aer-
uginosa,o rShigella flexneri [1, 7]. With the exception of S.
flexneri, the universal feature of these pathogens is
flagellin, which is typically translocated into the cytosol
by a bacterial secretion system and subsequently detected
by Ipaf leading to the assembly of the Ipaf-dependent
inflammasome. In addition to the dependence of non-
flagellated Shigella on Ipaf for caspase-1 activation, the
ability of mutated P. aeruginosa (PAKΔfliC), which does
not have flagellin, to activate caspase-1 confirms the
existence of a flagellin-independent pathway to Ipaf-
dependent inflammasome activation [7]. Discrepancies
between in vitro and in vivo response of Ipaf-deficient
macrophages to S. typhimurium infection further defined
the existence of parallel pathways to caspase-1 activation in
vivo. Whereas Ipaf-deficient macrophages exhibit exqui-
sitely attenuated caspase-1 activation and IL-1β secretion
in vitro [1], mice given this pathogen orally are not more
susceptible to infection than controls [8]. This is in contrast
to the enhanced susceptibility of caspase-1-deficient ani-
mals to S. typhimurium infection [8], thus confirming the
importance of integrated, multifaceted regulation, both
positive and negative, for effective inflammatory responses
in vivo.
The NLRP1 and AIM2 Inflammasomes
To date, the only drivers of NLRP1 inflammasome
activation identified is the Bacillus anthracis lethal toxin
(LT) and muramyl dipeptide (MDP) [9]. Initial clues
regarding the role of NLRP1 came from the observation
that various in-bred mouse strains are differentially sensi-
tive to LT, which was linked to polymorphism of the
NLRP1 locus [10]. Similarly to NLRP1, AIM2 has a highly
restricted spectrum of activating stimuli, being involved in
the detection of dsDNA. The HIN domain in AIM2's C
terminus interacts directly with dsDNA, facilitating recruit-
ment and activation of caspase-1 in an ASC-dependent
manner via its N-terminal pyrin domain (Fig. 1).
Despite key similarities among NLR members, it is
evident that a level of inflammasome regulation is
conferred by the ability of NLRs to specifically detect
different substrates. Conceivably, the nature of inflamma-
tory response requires that the sum total of inflammasome
activation in the cell be maintained below a threshold to
prevent unwanted damage to peripheral tissue, in addition
to maintaining sensitivity to negative regulation. Further-
more, the decision whether to undergo apoptosis or produce
cytokines appears to be inflammasome specific. Ipaf-
dependent inflammasome activation of caspase-1 results
predominantly in the rapid induction of pyrotopsis, an
inflammation-associated form of cell death, whereas
NLRP3-dependent inflammasome activation results pre-
dominantly in processing of IL-1β and IL-18. Again, this
provides a division of labor across multiple cellular
processes, presumably to prevent the failure to induce an
inflammatory response to all known pathogens if any one
process is deregulated. Another issue of critical importance
is whether there is reciprocal regulation of different
inflammasomes to confer substrate specificity, for example,
does engagement of the NLRP3 inflammasome result in
active neutralization of the IPAF-dependent inflammasome or
vice versa? This may be conferred at the level of subcellular
localization as inflammasome components are also known to
shuttle between compartments or perhaps due to differential
tissue expression patterns as has been demonstrated for
NLRP1 and NLRP3 in human tissues [11].
Once a productive immune response has been mounted,
the restraint of pro-inflammatory cytokine and chemokine
production becomes the primary goal. Inflammasome
activity can be suppressed by protein–protein interactions,
including the association of the NACHT domain of the
NLR protein with its LRR region prior to ligand recogni-
tion or sequestration of inflammasome components by
CARD- and PYD-containing proteins. For example, the
PYD-domain-containing Pyrin protein has a clear function
as a negative regulator of inflammasome activation as
individuals containing mutations of this protein have a
disorder called familial Mediterranean fever (Table 2), and
mice with targeted disruption of the C-terminal portion of
PYRIN exhibit increased endotoxin sensitivity and caspase-
1 activation [12]. Biochemically, this inhibition is based on
the interaction of the SPRY domain of PYRIN with NLRP3
and caspase-1 leading to attenuation of IL-1β secretion
[13]. CARD-domain-containing proteins with negative
regulatory capacities include CARD-only protein, ICE-
BERG, and inhibitor of CARD (INCA), and again function
by disrupting protein–protein interactions required for
inflammasome assembly. A thorough understanding of
these negative regulatory mechanisms will provide invalu-
able guidance for the rational design of novel anti-
inflammatory therapeutics.
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The host response to inflammatory stimuli is usually self-
limiting to prevent damage to neighboring tissues, but in
conditions such as familial periodic fever syndromes
(FPFS) and Muckle–Wells syndrome (MWS), there is a
persistent and rampant inflammatory response (Table 2).
These disorders are routinely caused by gain-of-function
germline mutations in the NLR signaling pathway, most
notably NLRP3. Approximately 60 disease-associated
mutations have been shown to cluster around the NACHT
domain, suggesting that alteration of the binding properties
results in spontaneous, deregulated assembly of the inflam-
masome and production of mature IL-1β. Indeed, in the
basal state, monocytes from MWS patients secrete more
mature IL-1β [14], and mice harboring mutations of
NLRP3 equivalent to the human disease exhibit hyperactive
inflammasomeleadingtounrestrained IL-1β production [15].
Emergent data also identifies a potential link between
unscheduled NLRP3 activation and the pathogenesis of
Alzheimer's disease. Aggregates of extracellular β-amyloid
are internalized by microglia leading to lysosomal damage,
activation of the NLRP3 inflammasome, and IL-1β
production [16]. Genetic variants of the autophagy gene
ATG16L1 are associated with the inflammatory bowel
disorder Crohn's disease, and disruption of this gene in
mice leads to hyper-responsiveness to endotoxin-induced
IL-1β production [17] as well as perturbed homeostasis of
Paneth cells of the intestine [18]. It remains to be
determined whether the autophagy pathway functions at
the level of inflammasome assembly and/or activation or
whether its primary role is to regulate the nonclassical
secretion of mature IL-1β. Diseases associated with
metabolic disturbance such as gout and pseudogout have
also been linked to deregulated inflammasome activity [19].
In the case of type II diabetes, glucotoxicity and lipotoxicity
induce oxidative stress, pro-inflammatory cytokine produc-
tion, and systemic inflammation leading to β-islet cell
destruction and insulin resistance [20]. Collectively, these
observations underscore the potential benefit of developing
therapies that neutralize the inflammasome.
Currently, therapeutics that neutralize downstream effec-
tors of inflammasome activity such as IL-1β show
remarkable promise for the treatment of these disorders.
Patients with FPFS and gout [19] respond to IL-1 receptor
antagonists, including recombinant IL-1R (anakinra and
rilonacept) and neutralizing human anti-IL-1β antibody
(canakinumab), and interestingly, even diseases with com-
plex etiology such as type II diabetes have been effectively
Table 2 Human Diseases Associated with Deregulated Inflammasome Activity
Condition Symptomatology Causal mutation(s) affecting inflammasome
Cryopyrinopathies
Familial hereditary periodic fever syndromes
Muckle–Wells syndrome (MWS) Fever, hives, sensorineural hearing
loss and arthritis
Mutations in CIAS1 (gene encoding
NLRP3) or the promoter region
Familial cold auto-inflammatory syndrome (FCAS) Cold-induced fevers, skin rash Mutations in CIAS1 (gene encoding
NLRP3) or the promoter region
Neonatal onset multisystem inflammatory disease
(NOMID)
Fever, hives, chronic aseptic meningitis Mutations in CIAS1 (gene encoding
NLRP3) or the promoter region
Familial Mediterranean fever (FMF) Fever, abdominal or chest pain, arthritis Mutations in MEFV (gene encoding pyrin)
Protein misfolding/aggregation diseases
Alzheimer's disease Cognitive impairment None identified; environmental + disease
susceptibility
Gout and pseudogout Joint swelling and pain, limited movement,
and red skin surrounding the affected joint
None identified; environmental + disease
susceptibility
Autoimmune diseases
Generalized vitiligo Loss of pigmentation due to melanocyte
destruction
Genetic variants of NLRP1
Type I diabetes Fatigue, excessive thirst, weight loss Genetic variants of NLRP1
Other
Guadeloupe variant periodic fever syndrome Cold-induced heterogeneous symptoms
including fever, joint or muscle pain,
sensorineural hearing loss, ulcers, and
lymphadenopathy
Mutations in FCAS2 (gene encoding
NLRP12)
Crohn's disease Abdominal pain, fever, diarrhea Genetic variants of ATG16L1;
polymorphism of Nod2
J Clin Immunol (2010) 30:485–490 489treated with anakinra [20]. In addition, these are the only
compounds currently approved by the Food and Drug
Administration for the treatment of cryopyrin-associated
periodic syndromes and rheumatoid arthritis [21]. These
products downregulate the inflammatory response by
“mopping up” inflammatory cytokines; however, although
IL-1β is certainly the most potent, it is not the sole cytokine
produced by inflammasome activation. IL-18 is also
produced in response to inflammasome activation [22]
and influences inflammation in a different manner to IL-1β,
most prominently by inducing a T helper type 2 response
[23]. This provides a link between the innate and adaptive
immune response and, therefore, represents an attractive
node for therapeutic targeting with compounds that neu-
tralize components upstream of inflammasome activation.
Conceivably, this approach could entail neutralization of
the putative secondary messenger and/or prevention of
ligand–receptor binding; however, this awaits experimental
verification.
Translating knowledge of the molecular basis for a
disease to rational drug design, in most cases, leads to
improved therapeutic index and reduced side effects. Much
is now known about what activates inflammasomes, how
inflammasomes assemble and become activated, and what
negative regulatory mechanisms exist to prevent the
deleterious effects of unrestrained pro-inflammatory cyto-
kine production. This provides a unique opportunity to
develop targeted therapeutics that can be used to treat the
variety of human disorders associated with deregulated
inflammasome activity.
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